In view of the updates as per Government Resolution No. Sankirna-2025/E-860421/Vishi-1 dated 11th February, 2026, Item No. 7 of the 39th Board of Governors (BoG) dated 05th June, 2026, Item No. 9 of the 36th Board of Governors dated 18th February, 2025, as per the roster approved by the Government of Maharashtra No.

Central Research Institute of Ayurveda was established on 21st of June 1971 at Cheruthuruthy in Thrissur district of Kerala. Over the years, the Institute has witnessed a tremendous upgradation in terms of infrastructural facilities and research activities. Although the institute was mostly known as a Central Research Institute for years, it was upgraded to the status of National Ayurveda Research Institute for Panchakarma in June 2017 for further preferment in the health care and research.

Aurobindo Pharma has successfully moved one step closer to completing its strategic acquisition of U.S.-based generic drug manufacturer Lannett Company after the U.S. Federal Trade Commission (FTC) approved the transaction subject to certain divestiture conditions.

The FTC announced that Aurobindo will divest four generic pharmaceutical products to Quagen Pharmaceuticals as part of a consent agreement designed to preserve competition in the U.S. generic medicines market. With this requirement in place, the proposed acquisition of Lannett can move forward toward completion.

GSK has announced an agreement to acquire Nuvalent, a clinical-stage biotechnology company focused on precision cancer therapies, in a transaction valued at approximately 10.6 billion USD. The deal significantly strengthens GSK's oncology pipeline and expands its presence in the rapidly growing lung cancer treatment market.